StockNews.AI
PBH
StockNews.AI
131 days

Prestige Consumer Healthcare to Release Fiscal 2025 Fourth Quarter and Year-End Earnings Results

1. PBH will release Q4 earnings on May 8, 2025. 2. A conference call will discuss earnings results at 8:30 a.m. ET. 3. Company's diverse product portfolio spans multiple health segments. 4. Earnings details could influence investor sentiment and stock price. 5. Replays of the call will be accessible for a week.

4m saved
Insight
Article

FAQ

Why Bullish?

Earnings releases can significantly impact stock prices; positive results expected from PBH's diverse portfolio.

How important is it?

Earnings results are crucial for stock performance and investor trust; significant influence expected.

Why Short Term?

Earnings announcements typically lead to immediate price adjustments; historical spikes noted after strong earnings.

Related Companies

CAGPGCLCHD
TARRYTOWN, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 fourth quarter and year-end earnings release on Thursday, May 8, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start. A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page. About Prestige Consumer Healthcare Inc. Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com. Investor Relations ContactPhil Terpolilli, CFA, 914-524-6819irinquiries@prestigebrands.com

Related News